Related Experiment Video
Updated: Jan 1, 2026

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
Published on: October 31, 2010
Evaluating the centralized purchasing policy for the treatment of hepatitis C: The Colombian CASE
Angela V Pérez1, Antonio J Trujillo2, Aurelio E Mejia3
1Johns Hopkins Bloomberg School of Public Health 101 North Wolfe Street Apt 415 Baltimore MD USA.
Insights
Colombia
Area of Science:
- Public Health
- Health Policy
- Pharmacoeconomics
Background:
- High drug costs for hepatitis C impede treatment access and adherence.
- The Colombian health care system implemented a strategy in 2017 to address this issue.
Purpose of the Study:
- To assess the effectiveness of Colombia's centralized purchasing strategy for hepatitis C drugs.
- Evaluate changes in drug prices, clinical outcomes, and stakeholder perspectives.
Main Methods:
- Policy implementation assessment utilizing data from the Ministry of Health and Colombian Fund for High-Cost Diseases.
- Analysis included price changes, clinical outcomes (cure rates), and stakeholder interviews.
- Follow-up period: October 2017 to October 2018, with 1069 patients.
Main Results:
- Drug prices decreased by over 90%, reducing total direct costs from $100,102,171.75 to $8,378,747.
- A 96% cure rate was achieved among treated patients.
- 53% of patients completed treatment and were cured within the study period.
Conclusions:
- Colombia's centralized purchasing strategy significantly reduced hepatitis C drug costs.
- The strategy demonstrated high effectiveness in achieving patient cures and improving cost-efficiency.
- This model offers a scalable solution for improving access to high-cost medications.
Abstract:
The high cost of drugs for hepatitis C limits access and adherence to treatment. In 2017, the Colombian health care system decided to design a strategy. It consisted of centralized purchasing, regulations, clinical practice guidelines, and direct observation of the treatment and follow-up of patients. The main objective of this study was to assess the centralized purchasing strategy in Colombia. The study design was a policy implementation assessment. We analyzed the change in prices, the clinical outcomes, and the opinions of stakeholders using data from the Ministry of Health. Additional information about effectiveness came from the Colombian Fund for High-Cost Diseases and semi-structured interviews of the stakeholders. The follow-up was from October, 2017 to October, 2018. The total number of patients reported in the cohort period was 1069. The number that finished 12 weeks of treatment, completed the follow-up for the case closure, and were considered cured through the end of October, 2018 was 563 (53%). The remainder, 506 patients (47%), are currently in treatment. A total of 543 of these treated patients (96%) were cured. After implementing this strategy, the drug prices decreased by more than 90% overall. Before implementation, the total direct cost was $100 102 171.75 dollars. Afterward, the cost was $8 378 747 dollars.
Related Concept Videos
Secondary Healthcare System
Drugs for Treatment of Ulcerative Colitis in IBD
Hepatic Drug Excretion: Influencing Factors

